CA2537226C - Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents - Google Patents
Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents Download PDFInfo
- Publication number
- CA2537226C CA2537226C CA2537226A CA2537226A CA2537226C CA 2537226 C CA2537226 C CA 2537226C CA 2537226 A CA2537226 A CA 2537226A CA 2537226 A CA2537226 A CA 2537226A CA 2537226 C CA2537226 C CA 2537226C
- Authority
- CA
- Canada
- Prior art keywords
- defibrotide
- tumor
- combination
- use according
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 229960004120 defibrotide Drugs 0.000 title claims abstract description 76
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims description 26
- 238000009472 formulation Methods 0.000 title claims description 25
- 239000002246 antineoplastic agent Substances 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 15
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 229960001924 melphalan Drugs 0.000 claims description 11
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 11
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 claims description 9
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 claims description 9
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 claims description 9
- 201000008275 breast carcinoma Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 230000009471 action Effects 0.000 abstract description 9
- 238000002512 chemotherapy Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229960001196 thiotepa Drugs 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 208000012766 Growth delay Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000002634 anti-blastic effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali-metal salt Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001714A ITMI20031714A1 (it) | 2003-09-05 | 2003-09-05 | Formazioni ad azione antitumorale. |
| ITMI2003A001714 | 2003-09-05 | ||
| US53934404P | 2004-01-28 | 2004-01-28 | |
| US60/539,344 | 2004-01-28 | ||
| PCT/EP2004/009723 WO2005023273A1 (en) | 2003-09-05 | 2004-08-27 | Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2537226A1 CA2537226A1 (en) | 2005-03-17 |
| CA2537226C true CA2537226C (en) | 2016-05-03 |
Family
ID=37064585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2537226A Expired - Fee Related CA2537226C (en) | 2003-09-05 | 2004-08-27 | Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
Country Status (23)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2598613A1 (en) * | 2005-03-03 | 2006-09-14 | Gentium S.P.A. | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| EP1872787A1 (en) * | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| CN103260627A (zh) | 2010-11-12 | 2013-08-21 | 真蒂奥姆有限公司 | 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd) |
| AU2012383169B2 (en) | 2012-06-22 | 2017-12-21 | Gentium S.R.L. | Euglobulin-based method for determining the biological activity of defibrotide |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| US10380734B2 (en) * | 2017-02-27 | 2019-08-13 | Aniket Bharat Parikh | System, method and computer program product for security analysis of jewelry items |
| SG11202000952PA (en) * | 2017-08-03 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Formulations comprising a nucleic acid in a high concentration |
| KR20210008478A (ko) | 2018-04-12 | 2021-01-22 | 재즈 파마슈티칼즈, 인코포레이티드 | 면역고갈과 관련된 사이토카인 방출 증후군 및 신경독성의 예방 및 치료를 위한 데피브로타이드 |
| US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| EP4110287A1 (en) | 2020-02-28 | 2023-01-04 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| US4853221A (en) * | 1980-11-13 | 1989-08-01 | Warner-Lambert Company | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer |
| IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| IT1252174B (it) * | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
| DE9202745U1 (de) | 1992-03-02 | 1992-04-30 | Howmedica Gmbh, 2314 Schoenkirchen | Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| HK1044896A1 (zh) * | 1997-04-28 | 2002-11-08 | Burcoglu Arsinur | 治疗hiv感染和与之有关的继发感染的方法 |
| WO1998054313A2 (en) | 1997-05-30 | 1998-12-03 | Mcgill University | Dna methyltransferase genomic sequences and antisense oligonucleotides |
| US6177545B1 (en) | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
| DE19740384A1 (de) | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
| WO2000074634A2 (en) * | 1999-06-03 | 2000-12-14 | Au Jessie L S | Methods and compositions for modulating cell proliferation and cell death |
| CA2433225A1 (en) * | 2000-12-29 | 2002-07-11 | Bio-Technology General, Inc. | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US6770753B2 (en) | 2001-07-05 | 2004-08-03 | The Trustees Of Columbia University In The City Of New York | Phosphorothioate antisense heparanase oligonucleotides |
| WO2003027313A2 (en) | 2001-09-24 | 2003-04-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| US20050032882A1 (en) * | 2002-03-06 | 2005-02-10 | Sophie Chen | Botanical extract compositions and methods of use |
| AU2003238189A1 (en) * | 2002-05-31 | 2003-12-19 | Klinikum Der Universitat Regensburg | Method for the protection of endothelial and epithelial cells during chemotherapy |
| BR0312483A (pt) * | 2002-07-01 | 2005-08-09 | Savient Pharmaceuticals Inc | Anticorpos e seus usos |
| AU2003252395A1 (en) | 2002-08-06 | 2004-03-11 | Toray Industries, Inc. | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| DE10244453A1 (de) | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
| US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| CA2598613A1 (en) | 2005-03-03 | 2006-09-14 | Gentium S.P.A. | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| EP1872787A1 (en) | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP1982722A1 (en) | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
-
2003
- 2003-09-05 IT IT001714A patent/ITMI20031714A1/it unknown
-
2004
- 2004-08-27 DK DK04764686T patent/DK1660100T3/da active
- 2004-08-27 RS YUP-2006/0154A patent/RS20060154A/sr unknown
- 2004-08-27 JP JP2006525096A patent/JP4671962B2/ja not_active Expired - Fee Related
- 2004-08-27 RU RU2006109210/15A patent/RU2348413C2/ru not_active IP Right Cessation
- 2004-08-27 MX MXPA06002489A patent/MXPA06002489A/es active IP Right Grant
- 2004-08-27 ES ES04764686T patent/ES2308223T3/es not_active Expired - Lifetime
- 2004-08-27 AU AU2004269896A patent/AU2004269896B2/en not_active Ceased
- 2004-08-27 CA CA2537226A patent/CA2537226C/en not_active Expired - Fee Related
- 2004-08-27 WO PCT/EP2004/009723 patent/WO2005023273A1/en not_active Ceased
- 2004-08-27 DE DE602004014787T patent/DE602004014787D1/de not_active Expired - Lifetime
- 2004-08-27 UA UAA200602374A patent/UA83500C2/uk unknown
- 2004-08-27 PT PT04764686T patent/PT1660100E/pt unknown
- 2004-08-27 CN CNB2004800253315A patent/CN100490820C/zh not_active Expired - Fee Related
- 2004-08-27 AT AT04764686T patent/ATE399558T1/de active
- 2004-08-27 ZA ZA200601852A patent/ZA200601852B/en unknown
- 2004-08-27 BR BRPI0414114-8A patent/BRPI0414114A/pt not_active IP Right Cessation
- 2004-08-27 EP EP04764686A patent/EP1660100B1/en not_active Expired - Lifetime
- 2004-08-27 KR KR1020067004451A patent/KR20060061367A/ko not_active Withdrawn
-
2006
- 2006-02-16 IL IL173785A patent/IL173785A0/en unknown
- 2006-02-28 IS IS8334A patent/IS8334A/is unknown
- 2006-03-02 US US11/366,243 patent/US8551967B2/en not_active Expired - Fee Related
- 2006-03-28 NO NO20061402A patent/NO20061402L/no not_active Application Discontinuation
-
2013
- 2013-09-06 US US14/019,674 patent/US20140005256A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006109210A (ru) | 2007-10-10 |
| PT1660100E (pt) | 2008-10-14 |
| CN100490820C (zh) | 2009-05-27 |
| ITMI20031714A1 (it) | 2005-03-06 |
| ES2308223T3 (es) | 2008-12-01 |
| KR20060061367A (ko) | 2006-06-07 |
| NO20061402L (no) | 2006-03-28 |
| ATE399558T1 (de) | 2008-07-15 |
| AU2004269896A1 (en) | 2005-03-17 |
| DK1660100T3 (da) | 2008-11-10 |
| ZA200601852B (en) | 2007-06-27 |
| US20140005256A1 (en) | 2014-01-02 |
| MXPA06002489A (es) | 2006-06-20 |
| US8551967B2 (en) | 2013-10-08 |
| IS8334A (is) | 2006-02-28 |
| RS20060154A (sr) | 2008-08-07 |
| JP2007504194A (ja) | 2007-03-01 |
| RU2348413C2 (ru) | 2009-03-10 |
| IL173785A0 (en) | 2006-07-05 |
| JP4671962B2 (ja) | 2011-04-20 |
| AU2004269896B2 (en) | 2009-11-19 |
| WO2005023273A1 (en) | 2005-03-17 |
| BRPI0414114A (pt) | 2006-10-31 |
| EP1660100B1 (en) | 2008-07-02 |
| US20060211646A1 (en) | 2006-09-21 |
| EP1660100A1 (en) | 2006-05-31 |
| UA83500C2 (uk) | 2008-07-25 |
| CN1845746A (zh) | 2006-10-11 |
| DE602004014787D1 (de) | 2008-08-14 |
| CA2537226A1 (en) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140005256A1 (en) | Formulations with anti-tumour action | |
| Gorelik et al. | Role of NK cells in the control of metastatic spread and growth of tumor cells in mice | |
| CZ20023228A3 (cs) | Farmaceutické prostředky k vyvolání účinku poąkozujícího cévy | |
| CN111343984A (zh) | 包含链黑菌素及雷帕霉素作为有效成分的癌症预防或治疗用药学组合物 | |
| RU2721116C2 (ru) | Композиции для лечения поражений тканей | |
| EA007530B1 (ru) | Противоопухолевые комбинации | |
| Oh et al. | Versatile and marvelous potentials of polydeoxyribonucleotide for tissue engineering and regeneration | |
| JP4950996B2 (ja) | 虚血性心疾患の治療に有用な、血管新生／血行再建のための医薬組成物及び方法 | |
| AU2007347370B2 (en) | Novel therapeutic use for treating leukaemia | |
| WO2014074529A1 (en) | Methods for treatment of primary cancer and cancer metastasis | |
| RU2396960C2 (ru) | Комбинированная противоопухолевая терапия и фармацевтические композиции для нее | |
| JPH07506584A (ja) | 血小板減少症治療における外因性グリコサミノグリカン類または誘導体の利用 | |
| Karita et al. | The antitumor effect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by caffeine | |
| JP2014502992A (ja) | 癌のための併用療法 | |
| EP3949970A1 (en) | Combined use of a-nor-5? androstane compound drug and anticancer drug | |
| US11957701B2 (en) | Therapy and new therapeutic agent for blood cancer | |
| Giuliani et al. | Combination chemotherapy and surgical adjuvant chemotherapy on MS-2 sarcoma and lung metastases in mice | |
| KR20210039414A (ko) | 암의 치료를 위한 병용 요법 | |
| Zhang et al. | OPEN ACCESS EDITED BY | |
| EA039817B1 (ru) | Лечение пациентов, перенесших трансплантацию гематопоэтических стволовых клеток | |
| Zaniboni et al. | Mitomycin-C, Vinblastine, and Lonidamine as Salvage Treatment of Advanced Breast Cancer: A Pilot Study | |
| TW201215396A (en) | Medicine for treating tumor and antitumor agent | |
| HK40011479A (en) | Method for administration of an anti-tumor agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210827 |